Nabeel Khan1, Carlos Vallarino2, Trevor Lissoos2, Umar Darr3, Michelle Luo2. 1. University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA. 2. Takeda Pharmaceuticals U.S.A., Inc., Deerfield, Illinois, USA. 3. Baylor University Houston, Houston, Texas, USA.
Abstract
BACKGROUND: Inflammatory bowel disease (IBD) treatment in the elderly is challenging in part because of increased risk of infections. The aim of our study was to determine the absolute and relative risk of infections among the elderly IBD patient population and to identify factors affecting the risk of infections in the overall IBD patient population. METHODS: A retrospective study of patients with IBD initiating corticosteroids, immunomodulators (IM), or biologic therapy (January 2010-December 2014) was conducted using the Truven Market Scan database. IM and biologic exposure were assessed in a time-dependent manner. ICD-9 codes identified infection during follow-up. A Cox proportional hazards model was fitted to gauge the association between age, other covariates, and infection risk. RESULTS: We identified 63,759 patients with IBD. We found 2664 infections (incidence rate [IR] = 16.95/100 person-years) among 8788 elderly patients with IBD and 10,515 (IR = 10.49/100 person-years) among the nonelderly group. Pneumonia (39.8%), sepsis (13.2%), and candidiasis (12.9%) were the most common infections in the elderly. Factors associated with a higher risk of infection included being elderly (HR: 1.27, P < 0.0001), anti-TNF therapy (HR: 1.64, P < 0.0001), IM therapy (HR: 1.32, P < 0.0001), and polypharmacy (HR: 1.32, P < 0.0001). CONCLUSIONS: Advanced age, anti-TNF (biologic) therapy, and IM therapy were associated with an increased risk of infection. Pneumonia was the most common infection among the elderly IBD population. Physicians should be mindful of these risks when prescribing medications for elderly patients with IBD, and ensure their patients are adequately vaccinated. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation 2019.
BACKGROUND:Inflammatory bowel disease (IBD) treatment in the elderly is challenging in part because of increased risk of infections. The aim of our study was to determine the absolute and relative risk of infections among the elderly IBDpatient population and to identify factors affecting the risk of infections in the overall IBDpatient population. METHODS: A retrospective study of patients with IBD initiating corticosteroids, immunomodulators (IM), or biologic therapy (January 2010-December 2014) was conducted using the Truven Market Scan database. IM and biologic exposure were assessed in a time-dependent manner. ICD-9 codes identified infection during follow-up. A Cox proportional hazards model was fitted to gauge the association between age, other covariates, and infection risk. RESULTS: We identified 63,759 patients with IBD. We found 2664 infections (incidence rate [IR] = 16.95/100 person-years) among 8788 elderly patients with IBD and 10,515 (IR = 10.49/100 person-years) among the nonelderly group. Pneumonia (39.8%), sepsis (13.2%), and candidiasis (12.9%) were the most common infections in the elderly. Factors associated with a higher risk of infection included being elderly (HR: 1.27, P < 0.0001), anti-TNF therapy (HR: 1.64, P < 0.0001), IM therapy (HR: 1.32, P < 0.0001), and polypharmacy (HR: 1.32, P < 0.0001). CONCLUSIONS: Advanced age, anti-TNF (biologic) therapy, and IM therapy were associated with an increased risk of infection. Pneumonia was the most common infection among the elderly IBD population. Physicians should be mindful of these risks when prescribing medications for elderly patients with IBD, and ensure their patients are adequately vaccinated. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation 2019.
Authors: Romina di Giuseppe; Sandra Plachta-Danielzik; Wolfgang Mohl; Martin Hoffstadt; Thomas Krause; Bernd Bokemeyer; Stefan Schreiber Journal: Int J Colorectal Dis Date: 2021-05-08 Impact factor: 2.571
Authors: Bharati Kochar; Virginia Pate; Michael D Kappelman; Millie D Long; Ashwin N Ananthakrishnan; Andrew T Chan; Robert S Sandler Journal: Clin Gastroenterol Hepatol Date: 2021-09-03 Impact factor: 13.576
Authors: Vera E R Asscher; Vince B C Biemans; Marieke J Pierik; Gerard Dijkstra; Mark Löwenberg; Sander van der Marel; Nanne K H de Boer; Alexander G L Bodelier; Jeroen M Jansen; Rachel L West; Jeoffrey J L Haans; Willemijn A van Dop; Rinse K Weersma; Frank Hoentjen; P W Jeroen Maljaars Journal: Aliment Pharmacol Ther Date: 2020-09-09 Impact factor: 8.171
Authors: María Fernández-Prada; Paula García-González; Alejandro García-Morán; Inés Ruiz-Álvarez; Covadonga Ramas-Diez; Carmen Calvo-Rodríguez Journal: Med Clin (Engl Ed) Date: 2021-08-09